latest news releases from the newsroom
Pain Therapeutics, Inc.
Remoxy Meets Primary Endpoint in Pivotal Phase III Study
SAN MATEO, Calif. and BRISTOL, Tenn., Dec. 6, 2007 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) and King Pharmaceuticals, Inc. (NYSE:KG) are pleased to announce positive results of a Phase III study of Remoxy(tm) in patients with chronic pain. Over 400 patients with osteoarthritis participated in this pivotal study. The study met the primary endpoint (p is less than 0.01) that was prospectively defined by the U.S. Food and Drug Administration (FDA) during the Special Protocol Assessment process.
Barrier Therapeutics, Inc.
Barrier Therapeutics to Present At the RBC Capital Markets Healthcare Conference On December 13, 2007
PRINCETON, N.J., Dec. 6, 2007 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that executive management will participate in the RBC Capital Markets Healthcare Conference to be held at The Westin New York at Times Square during December 12 through December 13, 2007. Al Altomari, Chief Operating Officer of Barrier, is scheduled to participate in a panel discussion on Thursday, December 13, at 10:00 a.m. EST.
SunOpta Acquires Neo-Nutritionals, Inc., Further Expands Vertically Integrated Production of Natural Health Products
TORONTO, Dec. 6, 2007 (PRIME NEWSWIRE) -- SunOpta Inc. (Nasdaq:STKL) (TSX:SOY) today announced that it has acquired 100% of the outstanding common shares of Neo-Nutritionals, Inc. ("Neo-Nutritionals"), located in Brantford, Ontario. Neo-Nutritionals develops and manufacturers a wide range of natural health products, in primarily tablet, capsule and powder form, and sells the products to both branded natural health products companies and as private label brands for mass market and natural health retailers. The transaction included a combination of cash and notes payable.